Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor

Journal of Medicinal Chemistry

Volumn 49, Issue 16, 2006, Pages 4971-4980

  Yang, Syaulan ^a   Chen, Shu Jen ^a   Hsu, Min Feng ^b,c,d   Wu, Jen Dar ^a   Tseng, Chien Te K ^e   Liu, Yu Fan ^a   Chen, Hua Chien ^a   Kuo, Chun Wei ^a   Wu, Chi Shen ^a   Chang, Li Wen ^a   Chen, Wen Chang ^a   Liao, Shao Ying ^a   Chang, Teng Yuan ^a   Hung, Hsin Hui ^a   Shr, Hui Lin ^c,d   Liu, Cheng Yuan ^a   Huang, Yu An ^a   Chang, Ling Yin ^a   Hsu, Jen Chi ^a   Peters, Clarence J ^e   Wang, Andrew H J ^b,c,d   Hsu, Ming Chu ^a   more..

^a TaiGen Biotechnology   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 TERT BUTOXY 1 [2 CYCLOHEXYL 1 [1 FORMYL 2 (2 OXOPYRROLIDIN 3 YL)ETHYLCARBAMOYL]ETHYLCARBAMOYL]PROPYL]CARBAMIC ACID BENZYL ESTER; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; TG 0205221; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONAVIRUS; COVALENT BOND; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR INTERACTION; MOUSE; NONHUMAN; RAT; SARS CORONAVIRUS; STRUCTURE ACTIVITY RELATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; CARBAMATES; CELL LINE; CERCOPITHECUS AETHIOPS; CORONAVIRUS 229E, HUMAN; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; DIPEPTIDES; DRUG STABILITY; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; SARS VIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 33746886624     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0603926     Document Type: Article

References (25)

1. Lee, N.; Hui, D.; Wu, A.; Chan, P.; Cameron, P.; Joynt, G. M.; Ahuja, A.; Yumg, M. Y.; Leung, C. B.; To, K. F.; Lui, M. D.; Szeto, C. C.; Chung, S.; Sung, J. J. Y. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003, 348, 1986-1994.
2. Drosten, C.; Günther, S.; Preiser, W.; ven der Werf, S.; Brodt, H.-R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A. M.; Berger, A.; Burguière, A.-M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J.; Müller, S.; Rickerts, V.; Stürmer, M.; Vieth, S.; Klenk, H.-D.; Osterhaus, A. D. M. E.; Schmitz, H.; Doerr, H. W. Identification of a novel coronavirus in patients with severe acute respiraory syndrome. N. Engl. J. Med. 2003, 348, 1967-1976.
3. Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P. E.; Dowell, S. F.; Ling, A.-E.; Humphrey, C. D.; Shieh, W.-J.; Guarner, J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J.-Y.; Cox, N.; Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J.; and the SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1953-1966.
4. Fouchier, R. A. M.; Kuiken, T.; Schutten, M.; van Amerongen, G.; van Doornum, G. J. J.; van der Hoogen, B. G.; Peins, M.; Lim, W.; Stöhr, K.; Osterhaus, A. D. M. E. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003, 423, 240.
5. Peiris, J. S. M.; Lai, S. T.; Poon, L. L. M.; Guan, Y.; Yam, L. Y. C.; Lim, W.; Nicholls, J.; Yee, W. K. S.; Yan, W. W.; Cheung, M. T.; Cheng, V. C. C.; Chan, K. H.; Tssang, D. N. C.; Yung, R. W. H.; Ng, T. K.; Yuen, K. Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319-1325.
6. WHO press release, 5 July, 2003. http://www.who.int/mediacentre/ news/releases/2003/pr56/en/.
7. Marra, M. A.; Jones, S. J. M.; Astell, C. R.; Holt, R. A.; Brooks-Wilson; A.; Butterfield, Y. S. N.; Khattra, J.; Asano, J. K.; Barber, S. A.; Chan, S. Y.; Cloutier, A.; Coughlin, S. M.; Freeman, G.; Girn, N.; Griffith, O. L.; Leach, S. R.; Mayo, M.; McDonald, H.; Montgomery, S. B.; Pandoh, P. K.; Petrescu, A. S.; Robertson, A. G.; Schein, J. E.; Siddiqui, A.; Smailus, D. E.; Stoot, J. M.; Yang, G. S.; Plummer, F.; Andonov, A.; Artsob, H.; Bastien, N.; Bernard, K.; Booth, T. F.; Bowness, D.; Czub, M.; Drebot, M.; Fernando, L.; Flick, R.; Garbutt, M.; Gray, M.; Grolla, A.; Jones, S.; Feldmann, H.; Meyers, A.; Kabain, A.; Li, Y.; Normand, S.; Stroher, U.; Tipples, G. A.; Tyler, S.; Vogrig, R.; Ward, D.; Watson, B.; Brunham, R. C.; Krajden, M.; Petric, M.; Skowronski, D. M.; Upton, C.; Roper, R. L. The genome sequence of the SARS-associated coronavirus. Science 2003, 300, 1399-1404.
8. Rota, P. A.; Oberste, M. S.; Monroe, S. S.; Nix, W. A.; Campagnoli, R.; Icenogle, J. P.; Peñaranda, S.; Bankamp, B.; Maher, K.; Chen, M.-H.; Tong, S.; Tamin, A.; Lowe, L.; France, M.; DeRisi, J. L.; Chen, Q.; Wang, D.; Erdman, D. D.; Peret, T. C. T.; Burns, C.; Ksiazek, T. G.; Rollin, P. E.; Sanchez, A.; Liffick, S.; Holloway, B.; Limor, J.; McCaustland, K.; Olsen-Rasmussen, M.; Fouchier, R.; Günther, S.; Osterhaus, A. D. M. E.; Drosten, C.; Pallansch, M. A.; Anderson, L. J.; Bellini, W. J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300, 1394-1399.
9. Ruan, Y.; Wei, C. L.; Ling, A. E.; Vega, V. B.; Thoreau, H.; Se Thoe, S. Y.; Chia, J.-M.; Ng, P.; Chiu, K. P.; Lim, L.; Zhang, T.; Chan, K. P.; Lin, E. L. O.; Ng, M. L.; Leo, S. Y.; Ng, L. F. P.; Ren, E. C.; Stanton, L. W.; Long, P. M.; Liu, E. T. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003, 361, 1779-1785.
10. Thiel, V.; Herold, J.; Schelle, B.; Siddell, S. G. Viral replicase gene products suffice for coronavirus discontinuous transcription. J. Virol. 2001, 75, 6676-6681.
11. Murphy, R. L. Reviving protease inhibitors: new data and more options. J. Acquired Immune Defic. Syndr. 2003, 33, S43-S52.
12. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Webber, S. E.; Marakovits, J. T.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Ford, C. E.; Burke, B. J.; Rejto, P. A.; Hendrickson, T. F.; Tuntland, T.; Brown, E. L.; Meador III, J. W.; Ferre, R. A.; Harr, J. E. V.; Kosa, M. B.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 1999, 42, 1213-1224.
13. (b) Tian, Q.; Nayyar, N. K.; Babu, S.; Chen, L.; Tao, J.; Lee, S.; Tibbetts, A.; Moran, T.; Liou, J.; Guo, M.; Kennedy, T. P. An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-L-(+)-glutamic acid dimethyl ester. Tetrahedron Lett. 2001, 42, 6807-6809.
14. (c) Dragovich, P. S.; Webber, S. E.; Prins, T. J.; Zhou, R.; Marakovits, J. T.; Johnson Jr., T. O. (Agouron Pharmaceuticals, Inc.) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis. U.S. Patent 6531452 B1, 2003.
15. Pr¢X) structure: Basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
16. Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; Gao, G. F.; Anand, H.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190-13195.
17. Hsu, M.-F.; Kuo, C.-J.; Chang, K.-T.; Chang, H.-C.; Chous, C.-C.; Ko, T.-P.; Shr, H.-L.; Chang, G.-G.; Wang, A. H.-J.; Liang, P.-H. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 2005, 280, 31257-31266.
18. Hsyu, P.-H.; Pithavala, Y. K.; Gersten, M.; Penning, C. A.; Kerr, B. M. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob. Agents. Chemother. 2002, 46, 392-397.
19. Zhang, K. E.; Hee, B.; Lee, C. A.; Liang, B.; Potts, B. C. M. Liquid chromatography-Mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease. Drug Metab. Dispos. 2001, 29, 729-734.
20. Otwinowski, Z. and Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
21. Collaborative computational project, the CCP4 suite: programs for crystallography. Acta Crystallogr., Sect. D 1994, 50, 760-763.
22. McRee, D. E. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 1999, 125, 156-165.
23. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D 1998, 54, 905-921.
24. Cheng, Y. and Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
25. Wallance, A. C.; Laskowski, R. A.; Thornton, J. M. Ligplot: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.